{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lantus%C2%AE", "query": { "intervention": "Lantus®" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 62, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lantus%C2%AE&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T18:32:25.602Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03211858", "title": "Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Insulin aspart", "type": "DRUG" }, { "name": "NovoLog/NovoRapid", "type": "DRUG" }, { "name": "Insulin glargine (HOE901)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 597, "start_date": "2017-08-02", "completion_date": "2019-01-12", "has_results": true, "last_update_posted_date": "2022-03-28", "last_synced_at": "2026-09-05T18:32:25.602Z", "location_count": 42, "location_summary": "Little Rock, Arkansas • Concord, California • Escondido, California + 35 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Concord", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Greenbrae", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03211858" }, { "nct_id": "NCT01117350", "title": "Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Insulin glargine", "type": "DRUG" }, { "name": "Liraglutide", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "35 Years to 75 Years" }, "enrollment_count": 978, "start_date": "2010-07", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2014-04-11", "last_synced_at": "2026-09-05T18:32:25.602Z", "location_count": 45, "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 39 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "La Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01117350" }, { "nct_id": "NCT00467649", "title": "A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "pramlintide acetate (Symlin)", "type": "DRUG" }, { "name": "rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine])", "type": "DRUG" }, { "name": "basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 112, "start_date": "2007-05", "completion_date": "2008-04", "has_results": true, "last_update_posted_date": "2015-04-14", "last_synced_at": "2026-09-05T18:32:25.602Z", "location_count": 37, "location_summary": "Northport, Alabama • Phoenix, Arizona • Loma Linda, California + 34 more", "locations": [ { "city": "Northport", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00467649" }, { "nct_id": "NCT02451137", "title": "A \"Real World\" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Insulin glargine, 300 U/ml", "type": "DRUG" }, { "name": "Insulin glargine, 100 U/ml", "type": "DRUG" }, { "name": "Insulin detemir", "type": "DRUG" }, { "name": "Background Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3304, "start_date": "2015-06-16", "completion_date": "2018-08-09", "has_results": true, "last_update_posted_date": "2019-09-10", "last_synced_at": "2026-09-05T18:32:25.602Z", "location_count": 407, "location_summary": "Birmingham, Alabama • Gulf Shores, Alabama • Guntersville, Alabama + 304 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Gulf Shores", "state": "Alabama" }, { "city": "Guntersville", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT02451137" }, { "nct_id": "NCT03687827", "title": "A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Insulin degludec", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 498, "start_date": "2018-10-02", "completion_date": "2019-12-27", "has_results": true, "last_update_posted_date": "2021-01-12", "last_synced_at": "2026-09-05T18:32:25.602Z", "location_count": 34, "location_summary": "Chandler, Arizona • Tucson, Arizona • Fresno, California + 28 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03687827" }, { "nct_id": "NCT00240253", "title": "A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "pramlintide acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 200, "start_date": "2005-10", "completion_date": "2006-06", "has_results": false, "last_update_posted_date": "2015-03-31", "last_synced_at": "2026-09-05T18:32:25.602Z", "location_count": 34, "location_summary": "Phoenix, Arizona • Concord, California • La Jolla, California + 31 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Concord", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Gatos", "state": "California" }, { "city": "Salinas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00240253" }, { "nct_id": "NCT01680341", "title": "Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "insulin degludec/insulin aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 272, "start_date": "2012-08-31", "completion_date": "2013-08-22", "has_results": true, "last_update_posted_date": "2018-04-02", "last_synced_at": "2026-09-05T18:32:25.602Z", "location_count": 28, "location_summary": "Goodyear, Arizona • Anaheim, California • Greenbrae, California + 24 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Spring Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01680341" }, { "nct_id": "NCT02666430", "title": "Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "Mylan's insulin glargine", "type": "DRUG" }, { "name": "Lantus®", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mylan Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "66 Years", "sex": "ALL", "summary": "18 Years to 66 Years" }, "enrollment_count": 127, "start_date": "2015-12", "completion_date": "2017-07", "has_results": true, "last_update_posted_date": "2022-03-03", "last_synced_at": "2026-09-05T18:32:25.602Z", "location_count": 39, "location_summary": "Fresno, California • Greenbrae, California • La Jolla, California + 36 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Northridge", "state": "California" }, { "city": "Tustin", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02666430" }, { "nct_id": "NCT04974528", "title": "Afrezza® INHALE-1 Study in Pediatrics", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 1", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Afrezza", "type": "BIOLOGICAL" }, { "name": "Rapid-acting Insulin Analog", "type": "BIOLOGICAL" }, { "name": "Basal Insulin", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Mannkind Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "4 Years to 17 Years" }, "enrollment_count": 319, "start_date": "2021-09-29", "completion_date": "2025-04-29", "has_results": false, "last_update_posted_date": "2025-05-06", "last_synced_at": "2026-09-05T18:32:25.602Z", "location_count": 39, "location_summary": "Los Angeles, California • Orange, California • Palo Alto, California + 35 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04974528" }, { "nct_id": "NCT02294474", "title": "Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "SAR342434", "type": "DRUG" }, { "name": "Humalog", "type": "DRUG" }, { "name": "insulin glargine HOE901", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 505, "start_date": "2015-01", "completion_date": "2016-02", "has_results": true, "last_update_posted_date": "2018-01-18", "last_synced_at": "2026-09-05T18:32:25.602Z", "location_count": 51, "location_summary": "Foley, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 45 more", "locations": [ { "city": "Foley", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02294474" } ] }